Phase 2 Study of Weekly Ficerafusp Alfa + Pembrolizumab vs Alternative Dosing in First‑Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Phase 2 Study of Weekly Ficerafusp Alfa + Pembrolizumab vs Alternative Dosing in First‑Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ficerafusp alfa
Sponsor:Bicara Therapeutics Inc.

Contact Research Centre

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug

France

Participants:18–64 years
Substances:Colestyramine
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Acute myeloid leukaemia

Not yet recruiting

Study of quizartinib‑based drug combination on measurable residual disease in adults 18‑60 with acute myeloid leukemia

Registered drugNo placebo

Study of quizartinib‑based drug combination on measurable residual disease in adults 18‑60 with acute myeloid leukemia

Registered drugNo placebo

France

Participants:18–64 years
Substances:Azacitidine
Sponsor:Centre Hospitalier Universitaire De Toulouse

Contact Research Centre

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Renal transplant+1

Not yet recruiting

Effect of Continuing Tacrolimus on Access to a Second Kidney Transplant in Patients with Renal Transplant Failure: A Randomized Controlled Trial

Registered drugNo placebo

Effect of Continuing Tacrolimus on Access to a Second Kidney Transplant in Patients with Renal Transplant Failure: A Randomized Controlled Trial

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Tacrolimus
Sponsor:University Hospital Of Clermont-Ferrand

Contact Research Centre

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational

France

Participants:18–64 years · 65+ years
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:LYSARC

Contact Research Centre

Mucormycosis

Not yet recruiting

Efficacy of isavuconazonium sulfate and amphotericin B drug combination for initial treatment of mucormycosis in adults

Registered drugNo placebo

Efficacy of isavuconazonium sulfate and amphotericin B drug combination for initial treatment of mucormycosis in adults

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amphotericin B
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Pneumonia+1

Not yet recruiting

Early Use of Dexamethasone versus Sodium Chloride Placebo in Patients with Severe Influenza-Induced Acute Hypoxemic Respiratory Failure (Phase III Randomized Trial)

Registered drug

Early Use of Dexamethasone versus Sodium Chloride Placebo in Patients with Severe Influenza-Induced Acute Hypoxemic Respiratory Failure (Phase III Randomized Trial)

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Centre Hospital Region Metz Thionville

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Chambery

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on multiple myeloma and various lymphomas, evaluating novel therapeutic combinations and treatment strategies.

Multiple Myeloma Treatments
Follicular Lymphoma Studies
Diffuse Large B-cell Lymphoma Research

Advanced trials exploring combinations of immunotherapy and targeted treatments for blood cancers.

02 Lung Cancer Research

Studies examining innovative treatments for non-small cell lung cancer, particularly focusing on immunotherapy approaches.

Immunotherapy Combinations
Elderly Patient Treatment Options
Novel Therapeutic Strategies

Emphasis on improving treatment outcomes through targeted and combination therapies.

03 Preventive Medicine

Research on pneumococcal vaccines and preventive treatments, including studies in specialized patient populations.

Vaccine Immunogenicity
Safety Studies
High-Risk Patient Groups

Focus on vaccine effectiveness during acute illness conditions.

04 Breast Cancer Studies

Clinical trials examining treatments for hormone-sensitive breast cancer, including targeted therapies and hormone treatment optimization.

Hormone Therapy Duration
Metastatic Disease Management
Biomarker Studies

Investigation of personalized treatment approaches based on molecular markers.

Back to France All countries